エクソソーム由来のmiR-493はMAD2L1の抑制を介して腹膜転移を有する胃癌患者へのパクリタキセルの腹腔内投与療法への抵抗性を惹起するMasahiro Makinoya(Tottori University)Institutional Repositories DataBase (IRDB)September 30, 2024Cited by 0SaveCiteExport RISWatch citationsRelated PapersExosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis|Scientific Reports|2024|11